[1]
|
American Cancer Society, “Cancer Facts and Figures 2010,” American Cancer Society, Atlanta, 2010.
|
[2]
|
M. L. Bernstein, J. M. Leclerc, G. Bunin, et al., “A Population-Based Study of Neuroblastoma Incidence, Survival, and Mortality in North America,” Journal of Clinical Oncology, Vol. 10, No. 2, 1992, pp. 323-329.
|
[3]
|
G. M. Brodeur, J. Pritchard, F. Berthold, et al., “Revisions of the International Criteria for Neuroblastoma Diagnosis, Staging, and Response to Treatment,” Journal of Clinical Oncology, Vol. 11, No. 8, 1993, pp. 1466-1477.
|
[4]
|
J. R. Park, A. Eggert and H. Caron, “Neuroblastoma: Biology, Prognosis, and Treatment,” Pediatric Clinics of North America, Vol. 55, No.1, 2008, pp. 97-120.
|
[5]
|
K. K. Matthay, J. G. Villablanca, R. C. Seeger, et al., “Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic Acid, Children’s Cancer Group,” The New England Journal of Medicine, Vol. 341, No. 16, 1999, pp. 1165-1173. doi:10.1056/NEJM199910143411601
|
[6]
|
S. Huang, “Back to the Biology in Systems Biology: What Can We Learn from Biomolecular Networks?” Briefings in Functional Genomics Proteomic, Vol. 2, No. 4, 2004, pp. 279-297. doi:10.1093/bfgp/2.4.279
|
[7]
|
A. Aranda-Anzaldo, “Cancer Development and Progression: A Non-Adaptive Process Driven by Genetic Drift. Acta Biotheoretica, Vol. 49, No. 2, 2001, pp. 89-108.doi:10.1023/A:1010215424196
|
[8]
|
E. Wang, A. Lenferink and M. O’Connor-McCourt, “Cancer Systems Biology: Exploring Cancer-Associated Genes on Cellular Networks,” Cellular and Molecular Life Sciences, Vol. 64, No. 14, 2007, pp. 1752-1762. doi:10.1007/s00018-007-7054-6
|
[9]
|
A. Balakrishnan, F. E. Bleeker, S. Lamba, et al. “Novel Somatic and Germline Mutations in Cancer Candidate Genes in Glioblastoma, Melanoma, and Pancreatic Carcinoma,” Cancer Reseaech, Vol. 67, No. 8, 2007, pp. 3545-3450. doi:10.1158/0008-5472.CAN-07-0065
|
[10]
|
H. H. Heng, “Cancer Genome Sequencing: The Challenges Ahead,” BioEssays, Vol. 29, No. 8, 2007, pp. 783-794. doi:10.1002/bies.20610
|
[11]
|
J. K. Lee, D. M. Havaleshko, H. Cho, et al., “A Strategy for Predicting the Chemosensitivity of Human Cancers and Its Application to Drug Discovery,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 104, No. 32, 2007, pp. 13086-13091.doi:10.1073/pnas.0610292104
|
[12]
|
Y. P. Mosse, M. Laudenslager, L. Longo, et al., “Identification of ALK as a Major Familial Neuroblastoma Predisposition Gene,” Nature, Vol. 455, No. 7251, 2008, pp. 930-935. doi:10.1038/nature07261
|
[13]
|
R. E. George, T. Sanda, M. Hanna, et al., “Activating Mutations in ALK Provide a Therapeutic Target in Neuroblastoma,” Nature, Vol. 455, No. 7251, 2008, pp. 975-978. doi:10.1038/nature07397
|
[14]
|
Network CGAR, “Comprehensive Genomic Characterization Defines Human Glioblastoma Genes and Core Pathways,” Nature, Vol. 455, No. 7216, 2008, pp. 1061-1068.
|
[15]
|
T. Sjoblom, S. Jones, L. D. Wood, et al., “The Consensus Coding Sequences of Human Breast and Colorectal Cancers,” Science, Vol. 314, No. 5797, 2006, pp. 268-274.doi:10.1126/science.1133427
|
[16]
|
J. P. Overington, B. Al-Lazikani, A. L. Hopkins, “How Many Drug Targets Are There?” Nature Reviews Drug Discovery, Vol. 5, No. 12, 2006, pp. 993-996.doi:10.1038/nrd2199
|
[17]
|
D. S. Wishart, C. Knox, A. C. Guo, et al., “DrugBank: A Knowledgebase for Drugs, Drug Actions and Drug Targets,” Nucleic Acids Research, Vol. 36, 2008, pp. D901- D906. doi:10.1093/nar/gkm958
|
[18]
|
G. Bollag, P. Hirth, J. Tsai, et al., “Clinical Efficacy of a RAF Inhibitor Needs Broad Target Blockade in BRAF-Mutant Melanoma,” Nature, Vol. 467, No. 7315, 2010, pp. 596-599. doi:10.1038/nature09454
|
[19]
|
E. L. Kwak, Y. J. Bang, D. R. Camidge, et al., “Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer,” The New England Journal of Medicine, Vol. 363, No. 18, 2010, pp. 1693-1703.doi:10.1056/NEJMoa1006448
|
[20]
|
J. Lamb, E. D. Crawford, D. Peck, et al., “The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease, Science, Vol. 313, No. 5795, 2006, pp. 1929-1935.
|
[21]
|
J. E. Staunton, D. K. Slonim, H. A. Coller, et al., “Chemosensitivity prediction by Transcriptional Profiling,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 98, No. 19, 2001, pp. 10787-10792. doi:10.1073/pnas.191368598
|
[22]
|
C. P. Webb, “Personalized Medicine: The Need for System Integration in the Design of Targeted Therapies,” In: R. Head, Ed., Computational and Systems Biology: Applications and Methods, Research Signpost, Kerala, 2009.
|
[23]
|
D. D. Von Hoff, J. J. Stephenson Jr., P. Rosen, et al., “Pilot Study Using Molecular Profiling of patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers,” Journal of Clinical Oncology, Vol. 28, No. 33, 2010, pp. 4877-4883.doi:10.1200/JCO.2009.26.5983
|
[24]
|
A. Tsimberidou, N. G. Iskander, D. S. Hong, J. J. Wheler, S. Fu, S. A. Piha-Paul, A. Naing, G. S. Falchook, F. Janku, R. Luthra, S. Wen and R. Kurzrock, “Personalized Medicine in a Phase I Clinical Trials Program: The M.D. Anderson Cancer Center Initiative,” Journal of Clinical Oncology, Vol. 29, 2011, pp. CRA2500.
|
[25]
|
C. F. Thorn, T. E. Klein, R. B. Altman, “Pharmacogenomics and Bioinformatics: PharmGKB,” The Pharmacogenomics Journal, Vol. 11, No. 4, 2010, pp. 501-505.doi:10.2217/pgs.10.15
|
[26]
|
Z. Dezso, Y. Nikolsky, T. Nikolskaya, et al., “Identifying Disease-Specific Genes Based on Their Topological Significance in Protein Networks,” BMC Systems Biology, Vol. 3, 2009, p. 36. doi:10.1186/1752-0509-3-36
|
[27]
|
W. Shi, M. Bessarabova, D. Dosymbekov, et al., “Functional Analysis of Multiple Genomic Signatures Demonstrates That Classification Algorithms Choose Phenotype-Related Genes,” The Pharmacogenomics Journal, Vol. 10, No. 4, 2010, pp. 310-323. doi:10.1038/tpj.2010.35
|
[28]
|
A. Vellaichamy, Z. Dezso, L. JeBailey, et al., “Topological Significance Analysis of Gene Expression and Proteomic Profiles from Prostate Cancer Cells Reveals Key Mechanisms of Androgen Response,” PLoS One, Vol. 5, No. 6, 2010, p. e10936.
|
[29]
|
J. S. Gheeya, Q. R. Chen, C. D. Benjamin, et al., “Screening a Panel of Drugs with Diverse Mechanisms of Action Yields Potential Therapeutic Agents Against Neuroblastoma,” Cancer Biology & Therapy, Vol. 8, No. 24, 2009, pp. 2386-2395. doi:10.4161/cbt.8.24.10184
|
[30]
|
S. Jones, X. Zhang, D. W. Parsons, et al., “Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses,” Science, Vol. 321, No. 5897, 2008, pp. 1801-1806. doi:10.1126/science.1164368
|
[31]
|
P. Northcott, A. Korshunov, H. Witt, et al., “Medulloblastoma Comprises Four Distinct Molecular Variants,” Clinical Oncology, Vol. 29, No. 11, 2011, pp. 1408-1414.
|